Pharmacists at the Forefront: Enhancing Targeted Therapy Implementation and Patient Outcomes in Advanced Gastric Cancer

Program Description

Despite an overall decline in incidence in gastric cancer in the United States, it remains a significant health burden. Outcomes for patients with advanced gastric cancer are often poor, and most patients require multiple lines of therapy. The development of new targeted therapies and immunotherapies has increased the number of available treatment options, and to ensure appropriate treatment selection oncology pharmacists must consider the efficacy of targeted therapies and immunotherapies based on key biomarkers. However, overlapping biomarkers may present a challenge, as there is often limited clinical evidence to guide treatment decisions in these patients. This webinar will cover the critical role of biomarker testing in gastric cancers as a strategy to guide treatment selection in the frontline and second-line settings. A data review from recent clinical trials informing regulatory decisions will also be discussed. Additionally, the program will emphasize the pharmacist's role in proactive management of treatment-related adverse effects, from medication-specific toxicities to immune-related adverse events, and will offer practical strategies for oncology pharmacists to provide dose modifications and supportive care to enhance patient safety and treatment adherence.
Target audience: Oncology pharmacists

Type of activity: Application

Release date: November 25, 2025

Expiration date: November 25, 2026

Time to complete activity: 1.0 hours

Learner level: Foundational, Intermediate

Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify key biomarkers and their relevance in selecting targeted therapies for patients with advanced/metastatic gastric cancer
• Explain the role of current and emerging targeted therapies in the management of advanced/metastatic gastric cancer, incorporating clinical guidelines, recent evidence, and biomarker data
• Employ strategies for managing adverse effects associated with targeted therapies, focusing on improving patient adherence and enhancing overall treatment outcomes
• Explore key considerations for the development and implementation of standardized order sets for novel targeted therapies in gastric cancer, including preparation, dosing, administration, and supportive care measures